Multiple myeloma and the treatment related renal recovery

Elena Zamagni, Simona Barbato, Michele Cavo. How I treathigh-risk multiple myeloma. Blood. 2022;139(19):2889-903.

Andrew J. Cowan, Damian J. Green, Mary Kwok, Sarah Lee, David G. Coffey, Leona A. Holmberg, et al. Diagnosis and Management of Multiple Myeloma. A Review. JAMA. 2022;327(5):464-77.

Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. The Lancet Oncology. 2021;22:e105-e18.

SV Rajkumar, MA Dimopoulos, APalumbo, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol, 15 (2014), pp. e538-e548.

RA Kyle, MA Gertz, TE Witzig, et al. Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.

3. M Kleber, G Ihorst, B Deschler, et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol. 2009;83:519-27.

BM Augustson, G Begum, JA Dunn, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219-26.

MA Dimopoulos, P Sonneveld, NLeung, et al. international myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34:1544-57.

WI Gonsalves, N Leung, SV Rajkumar, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5:e296.

MA Dimopoulos, PG Richardson, RSchlag, et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol. 2009;27:6086-93.

JP Fermand, F Bridoux, RA Kyle, et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood. 2013;122:3583-90.